MedPath

Assessment of the Uro-C Cystoscope for Use in Diagnostic Cystoscopy Procedures

Conditions
Bladder Tumor
Interventions
Device: Uro-C (Use of new cystoscope)
Registration Number
NCT03331705
Lead Sponsor
UroSee Corporation
Brief Summary

This is a prospective, multicenter, single-arm, open-label clinical usability study in subjects who are candidates for office diagnostic cystoscopy. The primary objective of this initial device assessment is to evaluate the performance of a new cystoscope for direct visualization of the urethra and bladder.

Detailed Description

A new cystoscope has been designed for female diagnostic cystoscopy, with a focus on promoting patient comfort, tolerability and safety while improving office efficiency. The cystoscope, named the Uro-C, is light-weight, ergonomic, handheld, battery-operated portable system that integrates a disposable cannula with a reusable handle that contains video electronics, is wireless capable, and has a liquid crystal display (LCD) monitor. Cystoscopy with the new system is performed in a standard manner to cystoscopy with currently available endoscopes, so risks are no different than when currently available endoscopes are used.

This is a prospective, multi-center, single-arm, open-label clinical usability study in subjects who are candidates for office diagnostic cystoscopy. The primary objective of this initial device assessment is to evaluate the performance of the cystoscope for direct visualization of the urethra and bladder.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
30
Inclusion Criteria
  1. Otherwise healthy adult (18 years of age or older) women presenting for cystoscopy for diagnostic purposes; and
  2. Ambulatory and able to undergo routine cystoscopy in the lithotomy position.
Exclusion Criteria
  1. History of prior bladder/urethral surgery other than TURBT; or
  2. History of interstitial cystitis; or
  3. Presence of urinary tract infection (UTI); or
  4. Gross hematuria; or
  5. History of pelvic radiation therapy; or
  6. Procidentia; or
  7. Unable to read, understand, and/or provide a ranking of pain level during the procedure; or
  8. Unable or unwilling to provide consent to participation in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Use of new cystoscopeUro-C (Use of new cystoscope)Patients in which the cystoscope is used.
Primary Outcome Measures
NameTimeMethod
Assessment of the utility and performance of the cystoscope by the physicianduring the procedure

Ranking with Likert Scale on ease of advancement, visibility of tissue and structures, and removal of the device

Secondary Outcome Measures
NameTimeMethod
Patient tolerance of the procedureduring and within 5 days after the procedure

Assess level of discomfort or adverse event associated with the procedure by the subject using the Likert Scale

Trial Locations

Locations (1)

Las Vegas Urology

🇺🇸

Las Vegas, Nevada, United States

© Copyright 2025. All Rights Reserved by MedPath